Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARDNASDAQ:ATXSNASDAQ:RPHMNASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$11.66+4.8%$9.29$4.88▼$19.58$252.98MN/A105,033 shs36,701 shsATXSAstria Therapeutics$4.96+3.8%$4.51$3.56▼$12.92$279.91M0.45372,434 shs456,271 shsRPHMReneo Pharmaceuticals$1.82$1.64$0.98▼$9.21$60.84M0.21250,384 shs437,523 shsRZLTRezolute$4.42+4.7%$3.42$2.22▼$6.19$377.99M1.01592,832 shs858,956 shs7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics+4.76%+18.74%-9.33%+2.46%+1,165,999,900.00%ATXSAstria Therapeutics+3.77%+21.27%-7.46%-20.39%-45.85%RPHMReneo Pharmaceuticals0.00%0.00%0.00%0.00%+8.98%RZLTRezolute+4.74%+15.40%+10.50%+11.06%+7.54%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AATXSAstria Therapeutics1.7344 of 5 stars3.61.00.00.02.21.70.0RPHMReneo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ARZLTRezolute2.8486 of 5 stars3.62.00.00.02.84.20.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 3.00Buy$31.25168.01% UpsideATXSAstria Therapeutics 3.25Buy$30.00504.84% UpsideRPHMReneo Pharmaceuticals 0.00N/AN/AN/ARZLTRezolute 3.14Buy$11.83167.72% UpsideCurrent Analyst Ratings BreakdownLatest RPHM, ATXS, RZLT, and AARD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2025AARDAardvark TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$21.00 ➝ $20.005/14/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$47.00 ➝ $47.005/14/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.004/29/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/28/2025ATXSAstria TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$47.004/28/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/1/2025AARDAardvark TherapeuticsRoyal Bank of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$21.00 ➝ $21.004/1/2025AARDAardvark TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$50.00 ➝ $50.003/27/2025AARDAardvark TherapeuticsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$22.00 ➝ $26.003/12/2025ATXSAstria TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$27.00 ➝ $28.003/11/2025ATXSAstria TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$16.00 ➝ $16.00(Data available from 6/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/AN/AN/AATXSAstria TherapeuticsN/AN/AN/AN/A$3.33 per shareN/ARPHMReneo PharmaceuticalsN/AN/AN/AN/A$2.66 per shareN/ARZLTRezoluteN/AN/AN/AN/A$1.65 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark TherapeuticsN/AN/A0.00∞N/AN/AN/AN/AN/AATXSAstria Therapeutics-$72.89M-$1.87N/AN/AN/AN/A-43.58%-29.36%8/11/2025 (Estimated)RPHMReneo Pharmaceuticals-$77.39M-$2.17N/AN/AN/AN/A-62.52%-56.36%N/ARZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.27%-62.41%N/ALatest RPHM, ATXS, RZLT, and AARD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025N/AAARDAardvark Therapeutics-$0.70-$0.71-$0.01-$0.71N/AN/A5/13/2025Q1 2025ATXSAstria Therapeutics-$0.48-$0.58-$0.10-$0.58N/AN/A5/13/2025Q3 2025RZLTRezolute-$0.22-$0.27-$0.05-$0.27N/AN/A3/11/2025Q4 2024ATXSAstria Therapeutics-$0.45-$0.44+$0.01-$0.44N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AATXSAstria TherapeuticsN/AN/AN/AN/AN/ARPHMReneo PharmaceuticalsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/AN/AN/AATXSAstria TherapeuticsN/A22.3822.38RPHMReneo PharmaceuticalsN/A57.8657.86RZLTRezoluteN/A9.309.30Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AATXSAstria Therapeutics98.98%RPHMReneo Pharmaceuticals90.98%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AATXSAstria Therapeutics2.90%RPHMReneo Pharmaceuticals17.90%RZLTRezolute18.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.70 millionN/AN/AATXSAstria Therapeutics3056.43 million54.80 millionOptionableRPHMReneo Pharmaceuticals3033.43 million27.44 millionOptionableRZLTRezolute4085.52 million49.40 millionOptionableRPHM, ATXS, RZLT, and AARD HeadlinesRecent News About These CompaniesRezolute, Inc. (NASDAQ:RZLT) is a favorite amongst institutional investors who own 77%June 3 at 2:20 AM | finance.yahoo.comRezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital HyperinsulinismMay 28, 2025 | globenewswire.comMan Group plc Makes New $425,000 Investment in Rezolute, Inc. (NASDAQ:RZLT)May 28, 2025 | marketbeat.comWoodline Partners LP Acquires 1,052,002 Shares of Rezolute, Inc. (NASDAQ:RZLT)May 26, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Lowered to "Sell" Rating by Wall Street ZenMay 24, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Invests $372,000 in Rezolute, Inc. (NASDAQ:RZLT)May 22, 2025 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Receives Average Recommendation of "Buy" from BrokeragesMay 22, 2025 | marketbeat.comRezolute, Inc.: Rezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateMay 21, 2025 | finanznachrichten.deHC Wainwright Analysts Lift Earnings Estimates for RezoluteMay 21, 2025 | marketbeat.comRezolute, Inc. (RZLT): Analysts See 260% Upside PotentialMay 20, 2025 | finance.yahoo.comCubist Systematic Strategies LLC Sells 92,168 Shares of Rezolute, Inc. (NASDAQ:RZLT)May 20, 2025 | marketbeat.comPoint72 Europe London LLP Purchases New Position in Rezolute, Inc. (NASDAQ:RZLT)May 18, 2025 | marketbeat.comRezolute, Inc. (NASDAQ:RZLT) Shares Purchased by Dimensional Fund Advisors LPMay 18, 2025 | marketbeat.comRezolute (RZLT) to Release Earnings on WednesdayMay 16, 2025 | marketbeat.comRezolute, Inc. Reports Progress on sunRIZE Enrollment and Breakthrough Therapy Designation for Ersodetug in Hypoglycemia TreatmentMay 16, 2025 | nasdaq.comRezolute, Inc. (NASDAQ:RZLT) Shares Purchased by OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLCMay 15, 2025 | marketbeat.comIntegral Health Asset Management LLC Boosts Stock Holdings in Rezolute, Inc. (NASDAQ:RZLT)May 14, 2025 | marketbeat.comJ. Goldman & Co LP Takes $1.14 Million Position in Rezolute, Inc. (NASDAQ:RZLT)May 14, 2025 | marketbeat.comRezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateMay 13, 2025 | globenewswire.comSchonfeld Strategic Advisors LLC Sells 272,368 Shares of Rezolute, Inc. (NASDAQ:RZLT)May 13, 2025 | marketbeat.comSusquehanna International Group LLP Buys 788,349 Shares of Rezolute, Inc. (NASDAQ:RZLT)May 7, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRPHM, ATXS, RZLT, and AARD Company DescriptionsAardvark Therapeutics NASDAQ:AARD$11.66 +0.53 (+4.76%) As of 06/3/2025 04:00 PM EasternAardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.Astria Therapeutics NASDAQ:ATXS$4.96 +0.18 (+3.77%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$4.97 +0.01 (+0.28%) As of 06/3/2025 04:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Astria Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema. The company is also developing STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, an immune disorder associated with loss of skin barrier function and itching. The company was formerly known as Catabasis Pharmaceuticals, Inc. and changed its name to Astria Therapeutics, Inc. in September 2021. Astria Therapeutics, Inc. was incorporated in 2008 and is headquartered in Boston, Massachusetts.Reneo Pharmaceuticals NASDAQ:RPHMReneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California.Rezolute NASDAQ:RZLT$4.42 +0.20 (+4.74%) Closing price 06/3/2025 04:00 PM EasternExtended Trading$4.43 +0.01 (+0.34%) As of 06:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas 3 Reasons Amazon Could Be the Best Tech Performer in June Ollie’s Q1 Earnings: The Good, the Bad, and What’s Next Applied Digital: CoreWeave’s AI Deal Lights a $7 Billion Fuse Qualcomm: A Technical Deep-Dive Confirms the Worst Rocket Lab Expands Into Payloads: Should You Be Paying Attention? Steel Dynamics Shares Climb After Tariff Announcement Palantir Soars on Government Deals as Valuation Debate Lingers Broadcom Earnings Preview: AVGO Stock Near Record Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
